Clinical trials: Lipemia
Hypercholesterolemia
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol
This study will evaluate the lipid-lowering effect and safety of colesevelam therapy administered to heterozygous familial pediatric patients 10 through 17 years of age who are on a stable dose of a pediatric-approved statin…
- Trial name
- NCT00145574
- Testing
- colesevelam HCl
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 194 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Metabolic Syndrome X
Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells
Thirty-six subjects with hyperlipidemia and metabolic syndrome and/or diabetes were randomized in a double-blind manner to either pravastatin 80 mg or atorvastatin 10 mg daily.
- Conditions
- Diabetes Mellitus, Metabolic Syndrome X, Hypercholesterolemia
- Trial name
- STOPCAP (NCT00166036)
- Testing
- Atorvastatin, Pravastatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Emory University
Atherosclerosis, Hypercholesterolemia
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
Background: Atherosclerosis (thickening of the artery walls caused by cholesterol and other deposits) commonly occurs in the heart vessels and carotid (neck) arteries of adults.
- Trial name
- NCT01212900
- Testing
- Statins, HMG CoA
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hypercholesterolemia
Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia
The purpose of this study is to assess the efficacy and safety of REGN727/SAR236553 in participants diagnosed with heterozygous familial hypercholesterolemia (heFH)
- Trial name
- NCT01266876
- Testing
- Alirocumab
- Where
- 22 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoporosis, Hypercholesterolemia
Effect of Atorvastatin on Bone-vascular Axis
Background: Circulating osteoprogenitors and RANKL expression in immune cells have been implicated in the pathogenesis of osteoporosis and vascular calcification.
- Trial name
- NCT02342015
- Testing
- Atorvastatin
- Volunteers
- 20 people
- Sponsor
- University of Padova
Adverse Effects, Cardiovascular Diseases
Self-Assessment Method for Statin Side-effects Or Nocebo
Front-line clinicians cannot currently test for an individual participant whether symptoms experienced are the pharmacological result of a statin or due to other phenomena.
- Conditions
- Adverse Effects, Cardiovascular Diseases, Hyperlipidemias
- Trial name
- SAMSON (NCT02668016)
- Testing
- Atorvastatin
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Imperial College London
Elevated Lipoprotein(a), Cardiovascular Disease
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS…
- Trial name
- NCT03070782
- Testing
- ISIS 681257
- Where
- 32 sites in United States, Canada and 3 more
- Volunteers
- 286 people
- Sponsor
- Akcea Therapeutics
Cardiovascular Diseases, Hypertension
Cardiovascular Risk Screening and Risk Reduction in Women Vets
Cardiovascular (CV) disease is the number one cause of death in American women, and all adult women are potentially at risk for CV disease.
- Conditions
- Cardiovascular Diseases, Hypertension, Hyperlipidemias, Dyslipidemias
- Trial name
- NCT02991534
- Testing
- CV Toolkit Components
- Where
- 4 sites in United States
- Volunteers
- 6,009 people
- Sponsor
- VA Office of Research and Development
Familial Hypercholesterolemia
Impact of LDL-cholesterol Lowering on Platelet Activation
The primary goal is to assess the impact of Evolocumab therapy on platelet function of familial hypercholesterolemia (FH) patients in a randomized, double blind study.
- Trial name
- NCT03331666
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Columbia University
Cardiovascular Disease, Hyperlipidemia
Effect of Evolocumab on Coronary Atherosclerosis
This study will quantify changes in coronary plaque volumes and plaque composition in patients treated with evolocumab. Previous intravascular ultrasound studies have shown that treatment with a lipid-lowering PCSK9 enzyme…
- Trial name
- NCT03689946
- Testing
- Evolocumab, 18F-NaF PET, CCTA
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Cedars-Sinai Medical Center
Hypercholesterolemia
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
Study of efficacy, safety, tolerability and quality of life of inclisiran (KJX839) vs placebo, on top of ongoing individually optimized lipid-lowering therapy, in participants with hypercholesterolemia
- Trial name
- V-DIFFERENCE (NCT05192941)
- Testing
- Inclisiran Sodium
- Where
- 136 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 1,770 people
- Sponsor
- Novartis Pharmaceuticals
Dyslipidemia, Hypercholesterolemia
A Study to Evaluate Fasting/Postprandial Serum Apolipoprotein B-48 (ApoB-48) Levels in Diabetic Participants With Normal to Moderately High Low Density Lipoprotein-C (LDL-C) Levels (MK-0653A-259 AM1)
This study will evaluate whether fasting/postprandial serum ApoB-48 levels are increased in diabetic participants compared to nondiabetic participants with the same range of serum LDL-C levels, and whether ApoB-48 levels can be…
- Trial name
- NCT01333436
- Testing
- Test Meal
- Where
- South Korea
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hypercholesterolemia
A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
This is a randomized, double-blind, placebo-controlled, multicenter, multiple ascending dose (MAD) study to evaluate the safety and tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of HTD1801 in overweight to…
- Trial name
- NCT03381287
- Testing
- HTD1801 Tablets, 500 mg, HTD1801 Tablets, 1000 mg, HTD1801 Tablets, 2000 mg
- Where
- 3 sites in Australia
- Volunteers
- 50 people
- Sponsor
- HighTide Therapeutics (Hong Kong) Limited
High Cholesterol, Coronary Artery Disease
Ezetimibe in Patients Hypo-responsive to Statins
Response to statin therapy for elevated low density lipoprotein is variable and may be influenced by cholesterol absorption. This study will evaluate whether combination therapy with atorvastatin/ezetimibe will be superior to…
- Trial name
- NCT00965055
- Testing
- Ezetimibe, Atorvastatin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of California, San Diego
Hypercholesterolemia
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
The purpose of this study is to determine whether ezetimibe/atorvastatin 10 mg/20 mg combination tablet is equivalent to the coadministration of ezetimibe 10 mg and atorvastatin 20 mg in lowering…
- Trial name
- NCT01370590
- Testing
- Atorvastatin, Ezetimibe, Ezetimibe/atorvastatin
- Volunteers
- 406 people
- Sponsor
- Organon and Co
Cardiovascular Disease
The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects
This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and…
- Trial name
- SPIRE-2 (NCT01975389)
- Testing
- bococizumab (PF-04950615)
- Where
- 1,595 sites in United States, Argentina and 33 more
- Volunteers
- 10,564 people
- Sponsor
- Pfizer
Hyperlipidemia
Telephone Based Management of Hyperlipidemia
The purpose of the study is to demonstrate that systematic self measurement of blood lipids reduces LDL cholesterol more effectively than standard care.
- Trial name
- NCT01212159
- Testing
- Self Monitoring Lipid Analyzer
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Temple University
Dyslipidemias, High Cholesterol
Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
- Conditions
- Dyslipidemias, High Cholesterol, Hypercholesterolemia
- Trial name
- ROSE (NCT04753606)
- Testing
- Obicetrapib
- Where
- 19 sites in United States
- Volunteers
- 120 people
- Sponsor
- NewAmsterdam Pharma
Hypercholesterolemia
A Study Comparing CoQ10 Levels While Taking 3 Different Statins
The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than Atorvastatin or Rosuvastatin.
- Trial name
- SPARQ (NCT01660191)
- Testing
- Pitavastin 4mg, Atorvastatin 20mg, Rosuvastatin 5mg
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- University of Kansas Medical Center
Hypercholesterolemia
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe [EZ] 10 mg/Atorvastatin [Atora] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg alone when administered to Japanese participants with…
- Trial name
- NCT02550288
- Testing
- Ezetimibe 10 mg, Atorvastatin 10 mg, Diet control/Daily Exercise
- Volunteers
- 309 people
- Sponsor
- Organon and Co